Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation and Depletion (2016 - 2019)

Amicus Therapeutics (FOLD) has disclosed Depreciation and Depletion for 6 consecutive years, with $991000.0 as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Depreciation and Depletion rose 2.27% year-over-year to $991000.0, compared with a TTM value of $4.2 million through Mar 2019, up 12.71%, and an annual FY2025 reading of $3.9 million, down 22.0% over the prior year.
  • Depreciation and Depletion was $991000.0 for Q1 2019 at Amicus Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.2 million in Q4 2018 and bottomed at $353000.0 in Q2 2015.
  • Average Depreciation and Depletion over 5 years is $834800.0, with a median of $896000.0 recorded in 2016.
  • The sharpest move saw Depreciation and Depletion decreased 10.86% in 2015, then surged 126.84% in 2016.
  • Year by year, Depreciation and Depletion stood at $395000.0 in 2015, then skyrocketed by 129.37% to $906000.0 in 2016, then increased by 22.96% to $1.1 million in 2017, then grew by 6.37% to $1.2 million in 2018, then dropped by 16.37% to $991000.0 in 2019.
  • Business Quant data shows Depreciation and Depletion for FOLD at $991000.0 in Q1 2019, $1.2 million in Q4 2018, and $1.1 million in Q3 2018.